Immunotherapy for bladder cancer

Current Urology Reports

Volumn 2, Issue 1, 2001, Pages 62-69

  Kamat, Ashish M ^a   Lamm, Donald L ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder Cancer; Intravesical Therapy; Superficial Bladder Cancer; Superficial Bladder Tumor; Transitional Cell Carcinoma

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

BLADDER TUMOR; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW; TRANSITIONAL CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; HUMANS; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 0035248112     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-001-0027-7     Document Type: Article

References (76)

1. Ro JY, Staerkel GA, Ayala Ag: Cytologic and histologic features of superficial bladder cancer (review). J Urol Clin North Am 1992, 19:435–449.
2. Heney NM, Ahmed S, Flanagan MJ, et al.: Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083–1086.
3. Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997, 80:762–765.
4. Vicente J, Laguna MP, Duarte D, et al.: Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 1991, 68:380–382.
5. Abel PD: Follow-up of patients with “superficial” transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993, 72:135–142. DOI: 10.1111/j.1464-410X.1993.tb16274.x
6. Palou J, Xavier B, Laguna P, et al.: In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology 1996, 47:482–484. DOI: 10.1016/S0090-4295(99)80481-6
7. Lamm DL, Blumenstein BA, Crawford ED, et al.: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991, 325:1205–1209. DOI: 10.1056/NEJM199110243251703
8. Guerin C: The history of BCG. In BCG Vaccine: Tuberculosis-Cancer, edn 2. Edited by Rosenthal SR. Littleton, MA: PSG Publishisng; 1980:35.
9. Pearl R: Cancer and tuberculosis. Proc Natl Acad Sci 1929, 9:97.
10. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976, 116:180–183.
11. Lamm DL, Thor DE, Harris SC, et al.: Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980, 124:38–40.
12. Becich MJ, Carroll S, Ratliff TL: Internalization of Bacille Calmette-Guérin by bladder tumor cells. J Urol 1991, 145:1316–1324.
13. Ratliff TL, Hudson MA, Catalona WJ: Strategy for improving therapy of superficial bladder cancer. World J Urol 1991, 9:95–99. DOI: 10.1007/BF00184040
14. Morales A, Nickel JC. Immunotherapy of superficial bladder cancer with BCG. World J Urol 1986, 3:209–214. DOI: 10.1007/BF00632180
15. Garden RJ, Liu BCS, Redwood SM, et al.: Bacillus Calmette-Guérin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction. J Urol 1992, 148:900–905.
16. Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL: Adverse impact of fibrin clot inhibitors on intravesical Bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 1990, 144:1362–1364.
17. Ratliff TL, Gillen DP, Catalona WJ: Requirement of thymus dependent immune response for BCG mediated anitumor activity. J Urol 1987, 137:155–159.
18. Davies M: Bacillus Calmette-Guérin as an antitumor agent. The interaction with cells of the mammalian immune system. Biochem Biophys Acta 1982, 651:143–147.
19. Haaff EO, Catalona WJ, Ratliff TL: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986, 136:970–974.
20. Morales A, Ottenhof PC: Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer 1983, 52:667–670. DOI: 10.1002/1097-0142(19830815)52:4<667::AID-CNCR2820520417>3.0.CO;2-C
21. Brosman SA: Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1992, 128:27.
22. Jansson OT, Morcos E, Brundin L, et al.: The role of nitric oxide in bacillus Calmette-Guerin mediated antitumour effects in human bladder cancer. Br J Cancer 1998, 78:588–592.
23. Lamm DL: Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 1985,134:40–47.
24. Herr HW, Pinsky CM, Whitmore WF Jr, et al.: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985, 25:119–123. DOI: 10.1016/0090-4295(85)90525-4
25. Herr HW, Laudone VP, Badalament RA, et al.: Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988, 6:1450–1455.
26. Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. In The Urologic Clinics of North America. Edited by Fair WR. Philadelphia: WB Saunders; 1991:525–528.
27. Pagano F, Bassi P, Milani C, et al.: Low dose BCG regimen in superficial bladder cancer therapy: is it effective? J Urol 1991, 146:32–35.
28. Melekos MD, Chionis H, Pantazakos A, et al.: Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 1993, 149:744–748.
29. Krege S, Giani G, Meyer R, et al.: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996, 156:962–926. DOI: 10.1016/S0022-5347(01)65673-8
30. Brake M, Loertzer H, Horsch R, Keller H: Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 2000, 55:673–678. DOI: 10.1016/S0090-4295(99)00591-9
31. Coplen DE, Marcus MD, Myers JA, et al.: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol 1990, 144:652–657.
32. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. In The Urologic Clinics of North America. Edited by Lamm DL. Philadelphia: WB Saunders; 1992:573–580.
33. De Jager R, Guinan P, Lamm D, et al.: Long term complete remission in bladder carcinoma in situ with intravesical Tice Bacillus Calmette Guerin—overview analysis of six pahse II clinical trials. Urology 1991, 38:507–514. DOI: 10.1016/0090-4295(91)80166-5
34. Akaza H, Hinotsu S, Aso Y, et al.: Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995, 75:552–559. DOI: 10.1002/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H
35. Mungan NA, Witjes JA: Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol 1998, 82:213–223.
36. Orsola A, Palou J, Xavier B, et al.: Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol 1998, 33:457–463. DOI: 10.1159/000019635
37. Klein EA, Rogatko A, Herr HW: Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 1992, 147:601–605.
38. Rosenbaum RS, Park MC, Fleischmann J: Intravesical bacille Calmette-Guerin therapy for muscle invasive bladder cancer. Urology 1996, 47:208–211. DOI: 10.1016/S0090-4295(99)80418-X
39. Lamm DL, DeHaven JI, Shriver J, Sarosdy MF: Percutaneous and intravesical prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol 1991, 145:738–740.
40. D’Ancona CA, Netto Jr NR, Claro JA, Ikari O: Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma. J Urol 1991, 145:498–501.
41. Morales A, Ottenhof P, Emerson L: Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 1981, 125:649–651.
42. Corti Ortiz D, Rivera Garay P, Aviles Jasse J, et al.: Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparision with other doses. Actas Urol Esp 1993, 17:239–242.
43. Kelley DR, Ratliff TL, Catalona WJ, et al.: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol 1985, 134:48–53.
44. Witjes JA, Fransen MPH, van der Meijden APM, et al.: Use of maintenance intravesical Bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Urol Int 1993, 51:67–72. DOI: 10.1159/000282516
45. Kavoussi LR, Torrence RJ, Gillen DP, et al.: Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol 1988, 139:935–940.
46. Palou J, Laguna P, Algaba F, et al.: High grade superficial transitional cell cercinoma of the bladder and/or CIS treatment with BCG: control vs maintenance treatment. Br J Urol 1997, 80(suppl):32.
47. Lamm DL, Blumenstein B, Sarsody M, et al.: Significant long-term patient benefits with BCG maintenance therapy:a South West Oncology Group study. J Urol 1997, 157:213. DOI: 10.1016/S0022-5347(01)65110-3
48. Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124–1129. A much awaited follow-up on the often quoted results previously only found in abstract form. This paper validates Lamm’s 6+3 protocol and shows a significant advantage of maintenance BCG therapy. DOI: 10.1016/S0022-5347(05)67707-5
49. Lamm DL, van der Meijden APM, Morales A, et al.: Incidence and treatment of complications of Bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992, 147:596–600.
50. De Boer EC, Steerenberg PA, van der Meijden APM, et al.: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 1992, 148:1577–1582.
51. DeHaven JI, Traynelis C, Riggs DR, et al.: Antibiotic and steroid therapy of massive systemic Bacillus Calmette-Guérin toxicity. J Urol 1992, 147:738–742.
52. Bohle A, Schuller J, Knipper A, Hofstetter A: Bacillus Calmette-Guerin treatment and vesicorenal reflux. Eur Urol 1990, 17:125–128.
53. Borden EC, Groveman DS, Nasu T, et al.: Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984, 132:800–803.
54. Torti FM, Shortliffe LD, Williams RD, et al.: Alpha-Interferon in superficial bladder cancer: a northern California oncology group study. J Clin Oncol 1988, 6:476–483.
55. Glashan R: A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol 1990, 144:658–661.
56. Kalble T, Beer M, Mendoza E, et al.: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 1994, 33:133–137.
57. Boccardo F, Cannata D, Rubagotti A, et al.: Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol 1994, 12:7–13.
58. Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al.: Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology 1997, 50:529–535. DOI: 10.1016/S0090-4295(97)00303-8
59. Rajala P, Liukkonen T, Raitanen M, et al.: Transurethral resection with perioperative instilation on interferonalpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study—Finnbladder III. J Urol 1999, 161:1133–1135. A well-designed randomized trial with a large number of patients that shows a benefit for intravesical chemotherapy after TURBT but not for immunotherapy. This is in accordance with the mechanisms of action of both modalities. DOI: 10.1016/S0022-5347(01)61609-4
60. Riggs DR, Tarry WF, DeHaven JI, et al.: Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol 1992, 147:212–214.
61. Stricker P, Pryor K, Nicholson T, et al.: Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996, 48:957–961. DOI: 10.1016/S0090-4295(96)00375-5
62. Bercovich E, Deriu M, Manferrari F, Irianni G: BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 1995, 67:257–260.
63. Brown DH, Wagner TT, Bahnson RR: Interferons and bladder cancer. Urol Clin North Am 2000, 27:171–178. A comprehensive review of the role of interferons in bladder cancer. DOI: 10.1016/S0094-0143(05)70245-7
64. Lamm DL, DeHaven JI, Riggs DR, et al.: Keyhole limpet hemocyanin immunotherapy of murine bladder cancer. Urol Res 1993, 21:33–37. DOI: 10.1007/BF00295189
65. Jurincic CD, Engelmann U, Gasch J, Klippel KF: Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 1988, 139:723–726.
66. Lamm DL, Dehaven JI, Riggs DR: Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000, 37(suppl):41–44. DOI: 10.1159/000052391
67. Sardosy MF, Lowe BA, Schellhammer PF, et al.: Bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 1996, 48:21–27. DOI: 10.1016/S0090-4295(96)90059-X
68. Witjes WP, Konig M, Boeminghaus FP, et al.: Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 1999, 36:576–581. DOI: 10.1159/000020051
69. Den OtterW, Dobrowolski Z, Bugajski A, et al.: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998, 159:1183–1186. DOI: 10.1097/00005392-199804000-00021
70. Eto M, Harada M, Tamada K, et al.: Antitumor activity of interleukin-12 against murine bladder cancer. J Urol 2000, 163:1549–1552. DOI: 10.1016/S0022-5347(05)67677-X
71. Clinton SK, Canto E, O’Donnell MA: Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 2000, 27:147–155. DOI: 10.1016/S0094-0143(05)70242-1
72. Lau BHS, Woolley JL, Marsh CL, et al.: Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in the control of murine transitional cell carcinoma. J Urol 1986, 136:701.
73. Riggs DR, DeHaven JI, Lamm DL: Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 1997, 79:1987. DOI: 10.1002/(SICI)1097-0142(19970515)79:10<1987::AID-CNCR21>3.0.CO;2-Q
74. Kamat AM, Lamm DL: Chemoprevention of urologic cancer. J Urol 1999, 161:1748–1760. DOI: 10.1016/S0022-5347(05)68793-9
75. Lamm DL, Riggs DR, Shriver JS, et al.: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994, 151:21.
76. Traynelis CL, Lamm DL: Current status of intravesical therapy for bladder cancer. In Urology Annual, vol 8. Edited by Rous SN. WW Norton; 1994:113–143.